Skip to main content
Fig. 2 | BMC Pediatrics

Fig. 2

From: Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study

Fig. 2

Participant flow chart. Group Var-HSA, participants receiving varicella vaccine produced without HSA (human serum albumin); Group Var + HSA, participants receiving varicella vaccine containing HSA; N, number of participants; ATP, according-to-protocol. Note: a Immunogenicity analyses were only planned in a sub-cohort of ~ 200 participants in each group. b Not due to an adverse event

Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us